Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Seeking Alpha on MSN19h
Biogen, Eisai Alzheimer’s drug review delayed in EUBiogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback